

CLAIMS

1. <sup>A molecule comprising</sup> ~~The use of a cC1qR binding domain~~ <sup>useful</sup> in the manufacture of a medicament to effect CUB domain functionality.

2. <sup>molecule</sup> ~~The use of a cC1qR binding domain~~ <sup>cC1qR</sup> according to claim 1, the <sup>binding</sup> domain forming part of a C1q receptor.

3. <sup>molecule</sup> ~~The use of a cC1qR binding domain~~ <sup>claim 1</sup> according to ~~either one of claims 1 or 2~~, the cC1qR binding domain being recombinant.

4. <sup>A molecule comprising</sup> ~~The use of an inhibitor of the cC1qR binding domain~~ <sup>useful</sup> in the manufacture of a medicament to inhibit CUB functionality.

5. <sup>molecule</sup> ~~The use of an inhibitor of the cC1qR binding domain~~ <sup>wherein</sup> according to claim 4, the inhibitory <sup>comprises</sup> ~~comprising~~ a cC1qR binding domain.

6. <sup>molecule according to claim 4, wherein the inhibitor of the cC1qR binding domain is useful</sup> ~~The use of an inhibitor of the cC1qR binding domain~~ according to either ~~one of claims 4 or 5~~ in the manufacture of a medicament for the treatment of complement activation involved in the initiation and maintenance of inflammation.

7. <sup>molecule</sup> ~~The use of an inhibitor of the cC1qR binding domain~~ <sup>wherein the inhibitor of the cC1qR binding domain is useful</sup> according to claim 6, in the manufacture of a medicament for the treatment of myocardial infarction, brain ischemia (stroke), gut ischemia, rheumatoid arthritis, systemic lupus erythematosus, burns, or immune complex nephritis.

- 15 -

A

molecule according to claim 4, wherein the inhibitor of the cClqR binding domain is useful

8. ~~The use of an inhibitor of the cClqR binding domain according to either~~  
~~one of claims 4 or 5~~ in the manufacture of a medicament for the treatment of amyloid  
plaques in Alzheimers disease.

A

A molecule comprising a cClqR binding domain

9. ~~The use of a cClqR binding domain or inhibitor thereof according to any~~  
~~one of the preceding claims, the cClqR binding domain having the sequence of any one~~  
of SEQ ID NOs: 1-3 or a partially modified form thereof.

A

pub B2 10. A method of treatment of the human or animal body comprising the use of  
a cClqR binding domain or an inhibitor thereof ~~according to any one of the preceding~~  
~~claims.~~

Add B3